CN114786678A - 诱导或增强法尼醇x受体(fxr)介导的转录反应的方法 - Google Patents

诱导或增强法尼醇x受体(fxr)介导的转录反应的方法 Download PDF

Info

Publication number
CN114786678A
CN114786678A CN202080078165.4A CN202080078165A CN114786678A CN 114786678 A CN114786678 A CN 114786678A CN 202080078165 A CN202080078165 A CN 202080078165A CN 114786678 A CN114786678 A CN 114786678A
Authority
CN
China
Prior art keywords
subject
fxr
compound
disease
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080078165.4A
Other languages
English (en)
Chinese (zh)
Inventor
郑永齐
林嵘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN114786678A publication Critical patent/CN114786678A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202080078165.4A 2019-11-20 2020-11-19 诱导或增强法尼醇x受体(fxr)介导的转录反应的方法 Pending CN114786678A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937964P 2019-11-20 2019-11-20
US62/937,964 2019-11-20
PCT/US2020/061257 WO2021102124A1 (en) 2019-11-20 2020-11-19 Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response

Publications (1)

Publication Number Publication Date
CN114786678A true CN114786678A (zh) 2022-07-22

Family

ID=75981072

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080078165.4A Pending CN114786678A (zh) 2019-11-20 2020-11-19 诱导或增强法尼醇x受体(fxr)介导的转录反应的方法

Country Status (7)

Country Link
US (1) US20220409631A1 (https=)
EP (1) EP4061377A4 (https=)
JP (1) JP2023502251A (https=)
KR (1) KR20220119367A (https=)
CN (1) CN114786678A (https=)
TW (1) TW202128200A (https=)
WO (1) WO2021102124A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI819307B (zh) * 2020-05-19 2023-10-21 吉亞生物科技股份有限公司 萜類化合物在治療或預防纖維化疾病中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159732A (zh) * 2011-12-15 2013-06-19 台湾利得生物科技股份有限公司 一种聚乙炔化合物、含其中的萃取物及其应用
CN103202863A (zh) * 2011-11-18 2013-07-17 善笙生物科技股份有限公司 一种用于预防或改善关节炎症状的药物组合物及其应用
CN103623409A (zh) * 2012-08-24 2014-03-12 台湾池研科技股份有限公司 樟芝酸衍生物与抗癌药物组合用于治疗和/或预防肿瘤
CN104606260A (zh) * 2014-12-25 2015-05-13 恩扬生物科技股份有限公司 用于辅助化疗药物的医药组合物及其用途
CN105311036A (zh) * 2015-11-26 2016-02-10 中国农业大学 樟芝酸h在防治药物性肝损伤中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015065983A1 (en) * 2013-10-29 2015-05-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
TWI623749B (zh) * 2015-04-30 2018-05-11 吳永昌 一種樟芝萃取物製備及分析方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103202863A (zh) * 2011-11-18 2013-07-17 善笙生物科技股份有限公司 一种用于预防或改善关节炎症状的药物组合物及其应用
CN103159732A (zh) * 2011-12-15 2013-06-19 台湾利得生物科技股份有限公司 一种聚乙炔化合物、含其中的萃取物及其应用
CN103623409A (zh) * 2012-08-24 2014-03-12 台湾池研科技股份有限公司 樟芝酸衍生物与抗癌药物组合用于治疗和/或预防肿瘤
CN104606260A (zh) * 2014-12-25 2015-05-13 恩扬生物科技股份有限公司 用于辅助化疗药物的医药组合物及其用途
CN105311036A (zh) * 2015-11-26 2016-02-10 中国农业大学 樟芝酸h在防治药物性肝损伤中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZI-WEI LI等: "Hepatoprotective activities of Antrodia camphorata and its triterpenoid compounds against CCl4-induced liver injury in mice", 《JOURNAL OF ETHNOPHARMACOLOGY》, vol. 206, pages 31 - 39, XP018529424 *

Also Published As

Publication number Publication date
EP4061377A4 (en) 2023-11-29
JP2023502251A (ja) 2023-01-23
EP4061377A1 (en) 2022-09-28
US20220409631A1 (en) 2022-12-29
TW202128200A (zh) 2021-08-01
KR20220119367A (ko) 2022-08-29
WO2021102124A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
KR102459500B1 (ko) 퀘르세틴 배당체를 함유하는 근위축 억제제
Ding et al. The HMGB1–TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis
Chenxu et al. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress
JP2019059750A (ja) 癌を治療するための方法及び組成物
JP2010502730A (ja) 癌の治療法
CN106714841A (zh) 治疗肝病的方法
RU2644635C2 (ru) Системы, способы и составы для лечения рака
KR102358632B1 (ko) 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
KR20140038388A (ko) 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
CA3130718A1 (en) Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
AU2017321322A1 (en) Compositions and methods for treatment of prostate cancer
CN114786678A (zh) 诱导或增强法尼醇x受体(fxr)介导的转录反应的方法
KR102843222B1 (ko) 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
CN103655542B (zh) 杨梅素在制备抑制铁调素表达的制剂中的应用
HK40077325A (en) Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response
EP2895149B1 (en) Synergistic anti-cancer composition and a process for the preparation thereof
KR102854371B1 (ko) 에트라비린의 대사성 질환 및 섬유화 질환 치료 용도
RU2007111682A (ru) Способ и набор для лечения и профилактики злокачественных опухолей женской репродуктивной системы с применением 9-оксоакридин-10-уксусной кислоты, и/или ее соли, и/или ее сложного эфира
US11992478B2 (en) Methods of using androgen receptor inhibitors as cancer therapeutics
KR20230128236A (ko) 신규한 포말리도마이드 유도체의 뇌질환 치료 용도
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
Van Neerven et al. Systemic but not local administration of retinoic acid reduces early transcript levels of pro-inflammatory cytokines after experimental spinal cord injury
CN103599108B (zh) 齐墩果酸在制备预防和治疗胆汁淤积症药物中的应用
CN115778944A (zh) 蛇床子素在制备改善或治疗认知功能障碍的药物中的用途
US12447147B2 (en) Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077325

Country of ref document: HK